4124-30-5

Basic information

• Product Name: DICHLOROACETIC ANHYDRIDE
• Synonyms: Acetic acid, dichloro-, anhydride;Aceticacid,dichloro-,anhydride;Anhydrid kyseliny dichloroctove;anhydridkyselinydichloroctove;Dichloroacetetic anhydride;Dichloroacetic acid anhydride;dichloro-aceticacianhydride;dichloro-aceticacid-anhydride
• CAS NO: 4124-30-5
• Molecular Formula: C₄H₂Cl₄O₃
• Molecular Weight: 239.87
• EINECS: 223-924-8
• Product Categories: Carbonyl Compounds;Carboxylic Acid Anhydrides;Organic Building Blocks
• Mol File: 4124-30-5.mol
• Article Data: 2

Chemical Properties

• Melting Point: ~30 °C
• Boiling Point: 214-216 °C(lit.)
• Flash Point: >230 °F
• Appearance: Clear colorless/Liquid After Melting
• Density: 1.574 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.151mmHg at 25°C
• Refractive Index: n20/D 1.483(lit.)
• Storage Temp.: Store below +30°C.
• Sensitive: Moisture Sensitive
• BRN: 512173
• CAS DataBase Reference: DICHLOROACETIC ANHYDRIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DICHLOROACETIC ANHYDRIDE(4124-30-5)
• EPA Substance Registry System: DICHLOROACETIC ANHYDRIDE(4124-30-5)

Safety Data

• Hazard Codes: C
• Statements: 20/21/22-34
• Safety Statements: 26-27-28-36/37/39-45
• RIDADR: UN 2923 8/PG 3
• WGK Germany: 3
• RTECS: AG6300000
• F: 21
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 4124-30-5(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless liquid after melting

Uses

Dichloroacetic anhydride was employed as an acylating agent for acylation of 10-Deacetylbaccatin III using Pseudomonas cepacia. It was also used in the preparation of cellulose dichloroacetates.

General Description

Dichloroacetic anhydride is an acylating agent and was evaluated for inducing autoimmune responses.

InChI:InChI=1/C4H2Cl4O3/c5-1(6)3(9)11-4(10)2(7)8/h1-2H

Upstream product

• 79-43-6 dichloro-acetic acid 
• 79-36-7 dichloroacethyl chloride 
• 7647-01-0 hydrogenchloride 
• 74-90-8 hydrogen cyanide 
• 75-36-5 acetyl chloride 
• 60-29-7 diethyl ether 
• 2156-56-1 sodium dichloroacetate 
• 108-24-7 acetic anhydride 

Downstream Products

• 100381-03-1 (2RS,3SR)-2-(2,2-dichloro-acetylamino)-3-hydroxy-3-(4-nitro-phenyl)-propionic acid ethyl ester 
• 39909-95-0 (1S,2S)-2-(2,2-dichloro-acetylamino)-1-(4-nitro-phenyl)-3-palmitoyloxy-propan-1-ol 
• 530-43-8 chloramphenicol Palmitate 
• 99852-64-9 1-dichloroacetoxy-1-(4-nitro-phenyl)-acetone 
• 99184-15-3 dichloro-acetic acid phenacylamide 
• 93464-25-6 (2RS,3RS)-2-(2,2-dichloro-acetylamino)-3-(4-nitro-phenyl)-3-palmitoyloxy-propan-1-ol 
• 82093-18-3 (1-D)Dichloressigsaeure 
• 100123-91-9 (+/-)-trans-4-(dichloroacetyl-amino)-5-(4-nitro-phenyl)-dihydro-furan-2-one 
• 100123-91-9 (+/-)-cis-4-(dichloroacetyl-amino)-5-(4-nitro-phenyl)-dihydro-furan-2-one 
• 24253-57-4 1-Dichloracetoxy-cyclohexen-⁽¹⁾ 
• 25227-88-7 N-(3-(2,2-dichloroacetamido)phenyl)-2,2-dichloroacetamide 
• 25255-93-0 N-[3-(2,2-Dichloro-acetylamino)-phenyl]-propionamide 
• 25256-17-1 N-[3-(2,2-Dichloro-acetylamino)-phenyl]-isobutyramide 
• 5468-76-8 2,2-dichloro-N,N-dimethylacetamide 

Relevant articles and documents

Ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug

Pt(iv) prodrugs have gained tremendous attention due to their indisputable advantages compared to cisplatin. Herein, new Pt(iv) derivatives with cinnamic acid at the first axial position, and inhibitor of matrix metalloproteinases-2 and-9, histone deacetylase, cyclooxygenase or pyruvate dehydrogenase at the second axial position are constructed to develop multi-action prodrugs. We demonstrate that Pt(iv) prodrugs are reducible and have superior antiproliferative activity with IC50 values at submicromolar concentrations. Notably, Pt(iv) prodrugs exhibit highly potent anti-tumour activity in an in vivo breast cancer model. Our results support the view that a triple-action Pt(iv) prodrug acts via a synergistic mechanism, which involves the effects of CDDP and the effects of axial moieties, thus jointly leading to the death of tumour cells. These findings provide a practical strategy for the rational design of more effective Pt(iv) prodrugs to efficiently kill tumour cells by enhancing their cellular accumulation and tuning their canonical mechanism.